Advertisement

Irish Journal of Medical Science

, Volume 182, Issue 1, pp 135–137 | Cite as

A series of patients on anti-TNF therapy referred to a multidisciplinary lung cancer service

  • C. O’Connell
  • M. Hensey
  • A. B. Mongey
  • D. J. Veale
  • S. C. Donnelly
Brief Report

Abstract

Background

Biological therapies have significantly improved the quality of life of patients with aggressive collagen vascular diseases. Blocking TNF activity may potentially confer a higher malignant potential for patients.

Aims

To identify patients to whom anti-TNF therapies were recently prescribed and were referred to a multidisciplinary lung cancer service.

Methods

Retrospective review of patients over an 18-month period who were referred to a multidisciplinary lung cancer service.

Results

Three patients who underwent recent anti-TNF therapies and presented with solid organ tumours. All had significant additional risks for cancer including smoking and family history and active connective tissue diseases with a past history of immunosuppressive therapies.

Conclusions

Our series highlights the potential malignant risk of anti-TNF theraphy to a general medical audience

Keywords

Anti-TNF therapy Rheumatoid arthritis Solid organ tumours Clinical registers 

Notes

Acknowledgments

SCD is supported by the Health Research Board (HRB) of Ireland and Science Foundation Ireland (SFI).

Conflict of interest

None of the authors or any commercial party have any benefit to disclosing this information.

References

  1. 1.
    Hashkes PJ, Uziel Y, Laxer RM (2010) The safety profile of biological therapies for juvenile idiopathic arthritis. Nat Rev Rheumatol 6:561–571PubMedCrossRefGoogle Scholar
  2. 2.
    O’Malley WE, Achinstein B, Shear MJ (1962) Action of bacterial polysaccharide on tumors, II. Damage of Sarcoma 37 by serum of mice treated with serratia marcescens polysaccharide, and induced tolerance. J Natl Cancer Inst 29:1169–1175Google Scholar
  3. 3.
    Beutler B, Cerami A (1989) The biology of cachectin/TNF—a primary mediator of the host response. Annu Rev Immunol 7:625–655PubMedCrossRefGoogle Scholar
  4. 4.
    Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM (2002) Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 46:3151–3158PubMedCrossRefGoogle Scholar
  5. 5.
    FDA Advisory Board (2009) Follow-up to the June 4, 2008 early communication about the ongoing safety review of tumor necrosis factor (TNF) blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174449
  6. 6.
    Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D (2011) Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf 20:119–130PubMedCrossRefGoogle Scholar
  7. 7.
    Lunt M, Watson KD, Dixon WG, Symmons DPM, Hyrich KL (2010) No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthr Rheum 62:3145–3153CrossRefGoogle Scholar
  8. 8.
    Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A (2010) BSRBR Control Centre Consortium, Symmons DPM, the BSR Biologics Register: drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-tnf therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 69:522–528PubMedCrossRefGoogle Scholar
  9. 9.
    Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, Stapel S, Tak PP, Aarden L, Dijkmans B (2006) Development of anti-infliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthr Rheum 54:711–715CrossRefGoogle Scholar
  10. 10.
    van Kuijk AW, de Groot M, Stapel SO, Dijkmans BA, Wolbink GJ, Tak PP (2010) Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis. Ann Rheum Dis 69:624–625PubMedCrossRefGoogle Scholar

Copyright information

© Royal Academy of Medicine in Ireland 2012

Authors and Affiliations

  • C. O’Connell
    • 1
  • M. Hensey
    • 1
  • A. B. Mongey
    • 2
  • D. J. Veale
    • 2
  • S. C. Donnelly
    • 1
  1. 1.Department of Respiratory Medicine, Education & Research CentreSt Vincent’s University HospitalDublin 4Ireland
  2. 2.Department of RheumatologySt Vincent’s University HospitalDublinIreland

Personalised recommendations